Amy B Heptinstall

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

M. Noble, J. Endicott, S. Cook, 2019, European journal of medicinal chemistry.

Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ob00099a

M. Noble, J. Endicott, I. Hardcastle, 2018, Organic & biomolecular chemistry.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor

M. Noble, J. Endicott, S. Cook, 2022, Journal of medicinal chemistry.

Cyclizations and fragmentations in the alkylation of 6‐chloro‐5‐hydroxy‐4‐aminopyrimidines with aminoalkyl chlorides

M. Waring, David M. Wilson, B. Golding, 2021, Journal of heterocyclic chemistry.

Recent advances in CDK inhibitors for cancer therapy.

I. Hardcastle, C. Cano, Amy B Heptinstall, 2018, Future medicinal chemistry.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

M. Noble, J. Endicott, M. Waring, 2021, Journal of medicinal chemistry.

Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites—Halogenated Probes of Druglike and Peptide-like Molecular Interactions

M. Noble, J. Endicott, I. Hardcastle, 2022, Journal of medicinal chemistry.